Menu
Not yet recruiting NCT07543926

New Treatment of Common Wart

No phase Interventional Common Warts (Verruca Vulgaris)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: PRF group, Vitamin D.
Who it may be relevant to
Registry conditions: Common Warts (Verruca Vulgaris). Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Evaluation Of Intralesional Platelet-Rich Fibrin Versus Intralesional Vitamin D In Treatment Of Common Warts

Overview

this study aims to compare the efficacy and safety of platelet rich fibrin injection versus intralesional vitamin D injection in the treatmentof common warts. PRF, as an autologous biological material , may enhance tissue regeneration and immune response.

Interventions

  • Biological PRF group
    intralesional PRF injection in common warts
  • Drug Vitamin D
    intralesional vitamin D injection in common wart

Primary outcome measures

  • treatment of common wart by PRF injection ( Mild response: < 50% reduction in lesion size , Moderate response: ≥ 50% reduction in lesion size , to measure the change in lesion size , is the patient satisfied or not ) [Time frame: 1 session every 2 weeks for 3 months]
  • changes in common warts after treatment by PRF (measuring complete clearance and recurrence of the lesions ,asking about patient satisfaction ) [Time frame: 6 months after the last session]

Eligibility criteria

Inclusion criteria

  • \- Age more than or equal to 18 years
  • Clinically and dermoscopically confirmed Common warts of both sex
  • patient not receiving previous treatment at least one month before recruitment in our study
  • Single or multiple lesions suitable for injection.

Exclusion criteria

  • Chronic Systemic desise (DM , HTN , Autoimmune , immunosuppressive disorders eg , lupus , renal or hepatic failure ) or Hematologic Conditions (anemia : hemoglobin level below 10 g/dl , thrombocytopenia : platelet count below 150,000 /µL ) Infectious Diseases , Local bacterial or fungal infection at the lesions .

Pregnancy, Lactation , patients who has hypersensitivity of vitamin D .

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Sohag University — Sohag

Identifiers

NCT: NCT07543926 · Soh-Med-26-3-16MS

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗